Benchmark Indices

Nifty50 takes back 17K, brings down weekly loss to less than 2%from 3.5%

In the preceding three trading sessions, the Sensex had gained 1,439 points, or 2.44 per cent, despite turbulence in global markets

All Adani group stocks rose on Friday, with flagship Adani Enterprises gaining the most at 17 per cent

Entire Adani pack gains for first time since Hindenburg report

A sell-off in Chinese technology stocks amid profit hits and price wars took its toll on Asian equities

The Nifty50, on the other hand, ended the session at 17,944, down 91 points or 0.5 per cent

After closing three weeks with losses, the benchmark indices ended the last week of 2022 with gains

Outperform most global peers even as returns moderate to just over 4% in 2022

Some investment bankers argued that the reason for tepid fundraising through QIPs and rights could also be due to the fact that companies this year were not in need of large capital

Business Standard's Puneet Wadhwa caught up with Gaurav Ratnaparkhi of Sharekhan by BNP Paribas, on the key levels he is tracking for the frontline indices and the 'must-have' stocks in your portfolio

During the week, the Sensex fell 2.4 per cent and the Nifty 2.5 per cent, their worst weekly decline since June 17, 2022

Foreign Portfolio Investors (FPIs) were net buyers to the tune of Rs 1,119 crore, according to provisional data from exchanges

But it remains a laggard on the bourses over the past decade

Sensex declines in 4 out of 5 sessions in the week, Nifty50 in 3 sessions

As foreign investors pumped money in stocks in India over the last week, Indian benchmark Indices, the BSE Sensex and NSE Nifty, reached new highs, despite economic chaos at the global level

Biocon, Gland Pharma, Mphasis and Bandhan Bank may move out, says note by Nuvama Alternative & Quantitative Research

The ADTV for the futures and options segment (both NSE and BSE combined) stood at Rs 147.5 trillion - a gain of 2 per cent MoM

Both shed 0.6% but end in green for second straight week; Broader markets play catch-up

The Pune-based vaccine producer's value has increased 20 per cent to Rs 2.2 trillion in the past one year

Market volatility and lacklustre 1-yr returns weigh on activity